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Purpose: Fentanyl buccal soluble film (FBSF) consists of a small, bilayered, water-soluble 
polymer film that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic 
circulation. The purpose of this study was to evaluate the absorption of fentanyl from FBSF in 
patients with cancer, with and without grade 1 oral mucositis, and to assess the tolerability of 
FBSF in this patient population.
Patients and methods: In an open-label, single-dose study, two groups of opioid-naive 
patients (ie, not receiving opioids on a regular basis) with cancer received a 200 µg dose of 
FBSF. Patients in cohort I (n = 7) had grade 1 mucositis, and patients in cohort II (n = 7) were 
age- and gender-matched controls without mucositis. The FBSF dose was placed on the area of 
mucositis in cohort I and on a matching location in cohort II. Blood samples were collected up 
to 4 hours after administration, and safety assessments were made throughout the study.
Results: Peak plasma concentration and area under the concentration–time curve from time 
0 to 4 hours post-dose values of patients in the grade 1 mucositis cohort were lower than those 
observed in patients without mucositis. There was no application site irritation reported in any 
patient, regardless of mucositis status. Mild somnolence was reported by two patients with 
mucositis. There were no deaths or serious adverse events reported in this study.
Conclusion: The results of this study indicate that application of FBSF to an area of grade 
1 mucositis does not result in increased fentanyl exposure or irritation of the mucosa. The 200 µg 
dose of FBSF was well tolerated.
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Introduction
Oral mucositis is defined as the inflammation and ulceration of the oral mucosa. In 
patients with cancer, it can be induced by chemotherapy and/or radiation therapy.1–4 
Although the incidence of mucositis varies depending on the location of the tumor and 
the course of treatment, occurrence of the condition is highest among patients with 
cancers of the head and neck, with approximately 80% of these patients developing 
mucositis.5,6
The presence of mucositis has a number of clinical implications in patients with 
cancer. Development of oral mucositis may ultimately impede a patient’s ability 
to drink, eat, and swallow if it progresses to more severe stages.7 In addition, the 
likelihood of developing infections of the mouth due to damaged oral mucosa and 
impaired immunity resulting from chemotherapy and radiation is greater in patients 
with mucositis. Oral mucositis may also impact the tolerability and efficacy of 
chemotherapeutic agents.8 Furthermore, patients may experience pain from mucositis Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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alone, or they may experience cancer breakthrough pain 
(BTP) that is related to their persistent cancer pain.
Transmucosal delivery of fentanyl is a common practice 
in the treatment of BTP, the transitory flare of pain that 
occurs in otherwise stable, persistent pain.9 Treatments for 
BTP include oral transmucosal fentanyl citrate (OTFC),10 
fentanyl buccal tablet (FBT),11 and fentanyl buccal soluble 
film (FBSF).12 The diffusion of fentanyl through the   buccal 
mucosa may be altered in patients with mucositis. This 
is a significant clinical issue as the absorption of fentanyl 
from these treatments may be impacted by the presence of 
mucositis.
Absorption of fentanyl delivered via FBT in the presence 
of oral mucositis has been studied previously.13 Fentanyl 
release from FBT occurs as the effervescent tablet   dissolves 
between the buccal mucosa and the upper gum.14 In a 
pharmacokinetic study to evaluate the exposure of FBT in 
patients with and without mild mucositis, the treatment was 
well tolerated, and overall exposure of fentanyl after FBT 
dosing was higher in the patients with mucositis compared 
with those without mucositis.13
FBSF was approved in the United States in 2009 as an 
opioid analgesic for the treatment of BTP in opioid-tolerant 
patients with cancer, 18 years of age and older.12 FBSF 
  consists of a small, bilayered, water-soluble polymer film that 
adheres to the buccal mucosa and rapidly delivers fentanyl 
into the systemic circulation.15 In a pharmacokinetic study 
conducted to determine the absorption of fentanyl from 
FBSF,16 volunteers were administered different formulations 
of fentanyl including FBSF administered as a single film and 
as four separate films. After dosing, the two FBSF doses 
were bioequivalent and both had an absolute bioavailability 
of 71%, with 51% of an administered dose absorbed through 
the oral mucosa.
As changes in the oral mucosa may affect the absorption 
of fentanyl from FBSF in patients with cancer and   mucositis, 
this study was undertaken to evaluate the absorption of 
  fentanyl from FBSF in patients with and without grade 1 
oral mucositis, and also to assess the tolerability of FBSF in 
that patient population.
Materials and methods
This was a Phase I, open-label, single-dose study in patients 
with cancer, conducted in the United States between   February 
and August 2007. The study protocol, amendments, and 
informed consent forms were reviewed and approved by a 
regional institutional review board (Western Institutional 
Review Board, Olympia, WA). This study was conducted 
in accordance with the ethical principles that have their 
  origins in the Declaration of Helsinki and the Code of Federal 
Regulations, Title 21, Part 50. Written informed consent to 
participate in the study was obtained from each subject at 
the screening visit prior to the conduct of any investigational 
procedures.
Patients
A complete oral examination was performed by a qualified 
clinician, and mucositis was graded according to the National 
Cancer Institute system.17 In this system, grade 1 mucositis is 
characterized by painless ulcers, erythema, or mild   soreness, 
and the patient is able to eat solids. Grade 2 mucositis is iden-
tified by the presence of painful erythema, edema, or ulcers, 
and the patient can eat or swallow. Patients with grade 3 
mucositis have painful erythema, edema, or ulcers   requiring 
intravenous hydration. Patients with grade 4 mucositis 
experience severe ulcerations or require parenteral or enteral 
nutritional support or prophylactic intubation.
Seven patients with grade 1 oral mucositis (cohort I) 
secondary to radiation or chemotherapy treatment of cancer 
and 7 age- and gender-matched control patients without 
oral mucositis (cohort II) were selected for participation in 
this study. Both cohorts included males and non-pregnant 
females aged 18 years or older. Patients were excluded if, 
in the opinion of the investigator, cardiopulmonary disease 
would increase the risk of respiratory depression, moderate 
or severe (grade 2–4) oral mucositis was present, the patient 
reported use of transdermal or transmucosal fentanyl for pain 
management within 7 days prior to the study period, and if 
the patient had a history of intolerance to fentanyl.   Exclusion 
criteria for cohort II included any patient with grade 1 or 
greater oral mucositis. Females could only participate in the 
study if they were not lactating and were either surgically 
sterile, postmenopausal, or using a highly effective method 
of contraception, and had a negative urine beta-human 
chorionic gonadotropin test result prior to administration of 
the study drug.
FBSF administration
Eligible patients received a single 200 µg dose of FBSF 
(Meda Pharmaceuticals Inc, Somerset, NJ), which was 
applied by study personnel to either the area of the mucosa 
that met the requirements for grade 1 oral mucositis 
(patients with mucositis; cohort I) or to a location of the 
mucosa   similar to the site used for the matched patient with 
mucositis (patients without mucositis; cohort II). Opioid 
tolerance was not an inclusion criterion. As the minimum Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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dose of FBSF available was used, oral naltrexone was not 
coadministered to block the respiratory depressive effects 
of fentanyl.
Pharmacokinetic analyses
Bioanalytical methods
The bioanalytical methods used in this study were reported 
previously.18 Venous blood samples (7 mL) were collected 
in K3-ethylenediaminetetraacetic acid (EDTA) Vacutainer® 
tubes (Becton Dickinson, Franklin Lakes, NJ) for measure-
ment of fentanyl plasma concentrations just prior to each 
FBSF dose and at the following times after drug admin-
istration: 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, and 4.0 hours. Blood 
sample tubes were inverted gently 10 times to mix the 
anticoagulant and then placed on ice. Within 30 minutes of 
collection, blood samples were centrifuged and the plasma 
fraction was transferred to two polypropylene screw-cap 
cryogenic storage tubes and frozen at –20°C until analysis 
for fentanyl. Plasma samples were analyzed for fentanyl 
using a validated liquid chromatography with tandem mass 
spectrometry procedure with a lower limit of quantification 
of 0.025 ng/mL and upper limit of 5.00 ng/mL based on the 
analysis of 0.500 µL of EDTA human plasma.18
Pharmacokinetic data analysis
Fentanyl plasma concentrations that were below the limit of 
quantification (BLQ) (,0.025 ng/mL) were assigned a value 
of zero if occurring from time zero up to the first measurable 
concentration. BLQ concentrations occurring in the terminal 
phase, elimination phase, or after peak   concentrations were 
treated as missing. All pharmacokinetic and statistical analyses 
were performed using unrounded concentration data.
The pharmacokinetic parameters determined for each 
patient and each treatment included the following: peak 
plasma concentration (Cmax), time to reach Cmax (tmax), 
and area under the plasma concentration–time curve 
from time 0 to 4 hours post-dose, calculated by the linear 
trapezoidal rule (AUC0–4). Cmax and tmax were determined 
from the individual patient’s concentration–time profiles. 
Plasma concentration–time data for each patient were 
analyzed by non-compartmental analysis using WinNonlin 
version 4.0 (Pharsight Corporation, Mountain View, CA). 
Pharmacokinetic calculations were based on actual sampling 
times.
FBSF residence time assessment
FBSF residence/dissolution was assessed just after applica-
tion and at 15, 30, 45, and 60 minutes after application.
safety evaluations
Adverse events (AEs) were monitored throughout the study. 
Pain and/or local irritation at the FBSF application site 
were measured on a 4-point scale (none, mild, moderate, or 
severe) just before application and at 0.5, 1.0, 2.0, 3.0, and 
4.0 hours after application. The number and percentage of 
patients reporting a response at each time point were sum-
marized per cohort.
Measurements of vital signs were performed at designated 
times throughout the study, and changes in respiratory rates 
were assessed through standard vital sign measurements.
statistical analysis
Descriptive statistics were calculated to summarize the 
pharmacokinetic parameters for patients with mucositis 
and without mucositis. Inferential statistical testing of these 
results was not the primary intent of this study and was not 
performed.
Results
study population
The demographic data of the patients included in this study 
are presented in Table 1. Fourteen patients (10 males and 
4 females) with a median age of 61.5 years were included. 
All patients completed the study. No AEs leading to 
premature discontinuation were reported. Only one patient 
had a   history of head and neck cancer (in cohort I), and no 
patient was treated for head and neck cancer at the time of 
this study. All patients in the mucositis group had examina-
tion findings consistent with mucositis at entry; five patients 
reported mild pain, one reported moderate pain, and one had 
severe baseline mucositis pain. Of the six patients with mild 
or moderate mucositis pain at baseline, five became pain 
free within 1 hour of FBSF administration, and one became 
pain free within 2 hours of dosing. The patient with severe 
pain at baseline became pain free 1 hour after dosing, and 
Table 1 Patient characteristics
Variable Cohort I patients  
with mucositis (n = 7)
Cohort II patients  
without mucositis (n = 7)
Sex, n (%)
  Male 5 (71) 5 (71)
  Female 2 (29) 2 (29)
Race, n (%)
  caucasian 6 (86) 4 (57)
  hispanic 1 (14) 3 (43)
Age, yearsa 65 (45–77) 57 (47–75)
height, cma 178 (152–185) 175 (165–183)
Weight, kga 89.5 (55.5–145.1) 90.5 (67.0–103.4)
Note: aMedian (range).Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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then mild pain returned through 4 hours. Pain at the site of 
application was determined to be due to mucositis, and not 
related to FBSF (Table 2).
Pharmacokinetic assessments
Pharmacokinetic parameters for FBSF for the two cohorts 
are presented in Table 3. Cmax of fentanyl after FBSF admin-
istration was achieved in 1 hour in both cohorts (Figure 1). 
The mean AUC0–4 (ie, from time 0 to 4 hours post-dose) was 
1.14 h⋅ng/mL in the oral mucositis cohort and 1.29 h⋅ng/mL 
in the cohort without oral mucositis. Thus, mean AUC0–4 for 
patients in both cohorts was similar, with patients in the oral 
mucositis cohort having a mean AUC0–4 of 88% of the value 
observed for those patients without oral mucositis. The range 
of maximum fentanyl concentrations was narrower in patients 
with mucositis compared with patients without mucositis. 
In addition, the maximum plasma fentanyl   concentration 
observed in the mucositis cohort was 73% of the value 
reported in the cohort without oral mucositis (1.13 ng/mL 
versus 1.55 ng/mL, respectively). Finally, the median and 
mean Cmax values in the oral mucositis cohort were 58% 
and 68% of the median and mean Cmax values, respectively, 
observed in the group without oral mucositis.
FBSF residence time assessment
No FBSF residence time was collected for the first seven 
patients (with mucositis) in this study. Fifteen minutes after 
application, four of the remaining seven patients had $10%  Table 2 Application site pain and/or irritation assessment
Scheduled time points/
pain and/or irritation 
severity, n (%)
Cohort I patients 
with mucositis  
(n = 7)
Cohort II patients 
without mucositis   
(n = 7)
Pre-dose
  none 0 (0) 7 (100)
  Mild 5 (71) 0 (0)
  Moderate 1 (14) 0 (0)
  severe 1 (14) 0 (0)
0.5 hours post-dose
  none 3 (43) 7 (100)
  Mild 3 (43) 0 (0)
  Moderate 1 (14) 0 (0)
  severe 0 (0) 0 (0)
1.0 hour post-dose
  none 6 (86) 7 (100)
  Mild 1 (14) 0 (0)
  Moderate 0 (0) 0 (0)
  severe 0 (0) 0 (0)
2.0 hours post-dose
  none 6 (86) 7 (100)
  Mild 1 (14) 0 (0)
  Moderate 0 (0) 0 (0)
  severe 0 (0) 0 (0)
3.0 hours post-dose
  none 6 (86) 7 (100)
  Mild 1 (14) 0 (0)
  Moderate 0 (0) 0 (0)
  severe 0 (0) 0 (0)
4.0 hours post-dose
  none 6 (86) 7 (100)
  Mild 1 (14) 0 (0)
  Moderate 0 (0) 0 (0)
  severe 0 (0) 0 (0)
Table  3  Pharmacokinetics  of  fentanyl  buccal  soluble  film  in 
opioid-tolerant patients with cancer, with and without mucositis
Parameter Cohort I patients  
with mucositis  
(n = 7)
Cohort II patients  
without mucositis  
(n = 7)
cmax, ng/mL 0.33 (0.19–1.13)  
Mean (SD): 0.47 (0.32)
0.57 (0.13–1.55)  
Mean (SD): 0.69 (0.54)
AUc0–4, h⋅ng/mL 0.98 (0.47–2.60)  
Mean (SD): 1.14 (0.71)
1.12 (0.39–2.97)  
Mean (SD): 1.29 (0.87)
Tmax, hours 1 (0.45–3.92)  
Mean (SD): 1.46 (1.15)
1 (0.50–1.50) 
Mean (SD): 1.04 (0.33)
Note: Data are median (range), unless otherwise indicated.
Abbreviations: AUc0–4, area under the concentration–time curve from time 0 to 4 
hours; cmax, peak plasma concentration; sD, standard deviation; Tmax, time to cmax.
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Figure 1 individual plasma concentrations of fentanyl following administration of 
fentanyl buccal soluble film in patients with cancer with oral mucositis (A) and 
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and ,50% of the film remaining, and three of the seven 
patients had $50% and ,100% of the film remaining. After 
30 minutes, one patient had trace amounts of the film present. 
There was no evidence of a relationship between Cmax and 
film residence time.
safety
There was no application site irritation in any patient, 
regardless of oral mucositis status. Two patients with 
mucositis reported mild somnolence following FBSF 
application. No treatment was administered, and both of 
these events resolved within 2 hours of reporting. No other 
AEs, serious AEs, or deaths were reported. Two patients with 
oral mucositis and six patients without oral mucositis had a 
post-baseline decrease in either systolic or diastolic blood 
pressure of $15 mmHg; however, none of these patients 
had symptoms associated with significant changes in blood 
pressure. There were no clinically meaningful changes in 
respiratory rates, with the maximum decrease being two 
breaths per minute.
Discussion
The effects of oral mucositis can impair the quality of life 
of patients with cancer and may limit the effectiveness and 
tolerability of cancer treatments.1–4,19–21 The objective of this 
study was to assess the absorption and tolerability profile of 
FBSF in patients with cancer with and without oral mucositis. 
The results of this study indicate that, although the presence of 
grade 1 oral mucositis may influence the absorption of FBSF, 
in contrast to FBT, bioavailability is decreased rather than 
increased. Time to maximum plasma fentanyl concentration 
was nearly 50% greater in the mucositis population (1.46 hours 
versus 1.00 hour), while maximum fentanyl concentration and 
overall exposure were lower in the mucositis population, 
suggesting the edema of the mucosa had a greater effect on 
mucosal drug absorption than local irritation. This finding is of 
practical importance: If the absorption of fentanyl in patients 
with mucositis was substantially greater, unexpectedly rapid 
rises in fentanyl plasma levels may lead to opioid-related AEs. 
In this study, film dissolution in most patients occurred in less 
than 30 minutes, irrespective of the buccal mucosa status, 
and there was no evidence of any relationship between Cmax 
and dissolution times. Also, after administration of FBSF, no 
AEs relating to the oral mucosa were reported. Finally, all 
patients with mucositis at the beginning of the study became 
mucositis pain free.
The pharmacokinetics of FBT in the presence of 
mucositis were evaluated previously.13 The study included 
eight patients with mucositis and eight patients without 
mucositis. Patients were instructed to place the tablet in the 
least inflamed area of the mucosa but not an area that was 
unaffected. Of the patients who participated in the FBT 
study, all of the patients in the group with mucositis had 
clinical grade 1 mucositis (ie, experienced erythema of the 
mucosa). Of those patients, only one experienced mucositis 
with a functional grade of 2 (ie, patient experienced the 
symptoms of mucositis but was able to consume a modified 
diet, and the respiratory symptoms observed did not impact 
the daily activities of the patient). After treatment with FBT, 
there was no difference in Cmax values after a 200 µg dose 
of FBT (1.14 ng/mL versus 1.21 ng/mL). Overall systemic 
exposure (AUC0–8) of fentanyl after FBT dosing was 32% 
higher in the patients with mucositis compared with those 
without mucositis (2.05 ng⋅hr/mL versus 1.55 ng⋅hr/mL). 
Although the difference in exposure was not statistically 
significant, this may have been due to the small sample 
size or the variability in the AUC measurement. As only 
one patient had grade 2 mucositis, no conclusion could be 
drawn about the impact of a more severe disease level on 
the absorption of fentanyl from FBT.13 The study of OTFC 
was limited to the tolerability of the application and did not 
examine the influence of severe mucositis on the absorption 
of fentanyl from OTFC.22 In the present study, the lower 
fentanyl exposure after FBSF dosing in the presence of 
mucositis suggests that alterations to the oral mucosal in 
patients with cancer with grade 1 mucositis membrane do 
not lead to an uncontrolled increase in the absorption of 
fentanyl. A possible clinical implication for this finding is 
that patients with cancer who are also experiencing mucositis 
may require slightly higher doses of FSBF than patients with 
cancer without mucositis.
When considering the difference in systemic exposure of 
fentanyl in patients with and without mucositis, the process 
of drug absorption via the oral mucosa and physiological 
changes to the oral mucosa in the presence of mucositis 
should be taken into account. Drug absorption via the oral 
mucosa occurs through a process of passive diffusion.23 
The rate of passive diffusion and amount of drug absorbed 
are influenced by a number of factors including a drug’s 
lipophilicity, the free drug concentration, the surface area 
associated with drug application, the length of time the drug 
is in contact with the oral mucosa, and the thickness of the 
oral mucosa.23,24 The oral mucosa consists of mucus, an epi-
thelium, the basal lamina, and connective tissue comprised 
of the submucosa and the lamina propia.23 The epithelium 
(∼150–250 µm) protects the underlying connective tissues Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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from damage.25 During the primary damage response and 
signal amplification phase of  mucositis, the epithelium thins. In 
addition to epithelium thinning, edema has also been observed 
in patients with cancer with mucositis   during radiation and 
chemotherapy.26 Decreases in epithelial thickness have also 
been observed in animal mucositis models.27,28 Our results 
indicate that the changes occurring in the buccal epithelium 
at the early stages of mucositis do not increase the passive 
diffusion of fentanyl, suggesting that fentanyl absorption is 
more influenced by parameters such as the absorption surface 
area and the duration of the absorption process than by the 
thickness of the epithelium.
Some limitations related to the study population and trial 
design should be considered in evaluating the results. Study 
limitations include the use of an open-label study design 
and the minimum dose of FBSF available (200 µg). Another 
limitation was the presence of mucosal pain in each of the 
patients with mucositis, which suggests that the severity 
of mucositis was higher than grade 1. The restriction of 
measurements of fentanyl concentrations to the interval of 
0.5 to 4.0 hours was another limitation. Although the sample 
size was comparable to the number of patients included 
in similar studies, the number of patients included in this 
study was small.13,22 In addition, collection of film residence 
times in controls was a study limitation. Finally, statistical 
analyses were not performed to compare the pharmacokinetic 
parameters.
Conclusion
The results of this study show that application of FBSF to an 
area of grade 1 mucositis does not result in increased fentanyl 
absorption. Use of the film did not produce local irritation, 
and the 200 µg dose of FBSF was well tolerated in patients 
with cancer with and without grade 1 mucositis.
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